Global Maple Syrup Urine Disease Treatment Market, By Type (Classic MSUD, Intermediate MSUD, Intermittent MSUD, and Others), Treatment Type (Medication and Surgery), Drugs (High-Calorie BCAA-Free Amino Acids, Caloric Supplementation, and Others), Route of Administration (Oral and Injectable), End- Users (Hospitals, Homecare, Specialty Clinics, and Others) – Industry Trends and Forecast to 2030.
Maple Syrup Urine Disease Treatment Market Analysis and Size
Major factors that are expected to boost the growth of the maple syrup urine disease treatment market in the forecast period are the ongoing clinical trial conducted by several pharmaceutical industries. Furthermore, a rise in the special designation from the regulatory authorities is further anticipated to propel the growth of the maple syrup urine disease treatment market. On the other hand, the inadequate operating revenue prospects for the research and development of targeted therapies by several pharmaceuticals are further projected to impede the growth of the maple syrup urine disease treatment market in the timeline period.
The maple syrup urine disease treatment market is expected to witness market growth at a rate of 11.20% in the forecast period of 2021 to 2028. Data Bridge Market Research report on the maple syrup urine disease treatment market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecast period while providing their impacts on the market’s growth. The rise in the demand for disease-specific novel treatments is escalating the growth of the maple syrup urine disease treatment market
Data Bridge Market Research analyses that the Maple Syrup Urine Disease Treatment market, which was USD 8,935 Million in 2022, would rocket up to USD 19,652 Million by 2030 and is expected to undergo a CAGR of 11.20% during the forecast period. This indicates the market value. “Intermittent MSUD” dominates the type segment of the Maple Syrup Urine Disease Treatment market. The growing awareness among healthcare professionals and the general population about maple syrup urine disease (MSUD) drives the demand for effective treatment options. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Maple Syrup Urine Disease Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Type (Classic MSUD, Intermediate MSUD, Intermittent MSUD, and Others), Treatment Type (Medication and Surgery), Drugs (High-Calorie BCAA-Free Amino Acids, Caloric Supplementation, and Others), Route of Administration (Oral and Injectable), End- Users (Hospitals, Homecare, Specialty Clinics, and Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of the Middle East and Africa
|
|
Market Players Covered
|
CENTOGENE AG – Germany, Acer Therapeutics Inc. (U.S.), HemoShear Therapeutics, LLC (U.S.), Recordati SpA – Italy, Jo Mar Laboratories (U.S.), Siddhi Vinayaka Spechem Private Limited (India), Baxter (U.S.), EXOCOBIO (South Korea), Pfizer Inc. (U.S.), Codexis, Inc. (U.S.), Homology Medicines, Inc. (U.S.), Mendel Tijssen BV Netherlands, Biomarin Pharmaceutical Inc. (U.S.), Vitaflo International Ltd. (U.S.), Mead Johnson & Company, LLC (U.S.), Nutricia Advanced Medical Nutrition (Netherlands), Daiichi Sankyo Company, Limited (Japan), Chiesi Farmaceutici S.p.A. (Italy)
|
|
Market Opportunities
|
|
Market Definition
Maple syrup urine disease is also called branched-chain ketoaciduria, which is a hereditary metabolic disorder in which the body is incapable of understanding certain protein building blocks that are known as amino acids properly because of the absence of an enzyme known as BCKDC (branched-chain alpha-keto acid dehydrogenase complex). These enzymes are essential to break down the three branched-chain amino acids (BCAAs) Isoleucine, Leucine, and Valine in the body.
Maple Syrup Urine Disease Treatment Market Dynamics
Drivers
- Increasing Awareness
Growing awareness among healthcare professionals and the general population about maple syrup urine disease (MSUD) drives the demand for effective treatment options.
- Technological Advancements:
Advances in diagnostic techniques, genetic testing, and therapeutic interventions improve the management and treatment of MSUD, leading to better patient outcomes.
Opportunities
- Research and Development
Ongoing research and development activities focused on understanding the disease mechanism and developing innovative treatment approaches present significant opportunities for advancements in MSUD treatment.
- Collaboration and Partnerships
Collaborations between pharmaceutical companies, research institutions, and advocacy groups can foster innovation, accelerate drug development, and improve access to treatment options for MSUD patients.
Restraints
- High Treatment Costs
The cost of specialized treatments, including enzyme replacement therapy and dietary management, can be a significant barrier for patients and healthcare systems, limiting access to effective therapies.
Challenges
- Limited Treatment Options
Currently, a limited number of approved treatment options specifically target MSUD. Developing novel and more effective therapies for MSUD remains a challenge.
Maple syrup urine disease is also called branched-chain ketoaciduria, which is a hereditary metabolic disorder in which the body is incapable of understanding certain protein building blocks that are known as amino acids properly because of the absence of an enzyme known as BCKDC (branched-chain alpha-keto acid dehydrogenase complex). These enzymes are essential to break down the three branched-chain amino acids (BCAAs) Isoleucine, Leucine, and Valine, in the body.
Recent Development
- In Feb 2022, Relief Therapeutics Holding SA announced a collaboration with Acer Therapeutics and has been granted a new patent by the United States Patent and Trademark Office (USPTO) for specific claims related to ACER-001 (sodium phenylbutyrate). The FDA is currently reviewing Acer Therapeutics' New Drug Application (NDA) for ACER-001 to treat UCDs, with a target action date of June 5, 2022, under the Prescription Drug User Fee Act (PDUFA).
Global Maple Syrup Urine Disease Treatment Market Scope
The maple syrup urine disease treatment market is segmented on the basis of type, treatment type, drugs, route of administration, and end users. The growth among segments helps you analyze niche pockets of development and strategies to approach the market and determine your core application areas and the difference in your target market.
Type
- Classic MSUD
- Intermediate MSUD
- Intermittent MSUD
- Others.
Treatment Type
- Medication
- Surgery
Drug
- High-calorie BCAA-free amino acids
- Caloric supplementation
- Others
Route of Administration
- Oral
- Injectable High-calorie BCAA-free amino acids
Route of Administration
- Hospitals
- Homecare
- Specialty clinics
- Others.
Maple Syrup Urine Disease Treatment Market Regional Analysis/Insights
The maple syrup urine disease treatment market is analyzed, and market size information is provided by country, type, treatment type, drugs, route of administration, and end users, as referenced above.
The countries covered in the maple syrup urine disease treatment market report are the U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of the Middle East and Africa.
North America dominates the maple syrup urine disease treatment due to the rise in the incidence of obesity and diabetes. Furthermore, an increase in healthcare expenses and growing alertness regarding metabolic disorders will further boost the growth of maple syrup urine disease treatment in the region during the forecast period.
Asia-Pacific is projected to observe a significant amount of growth during the forecast period of 2023 to 2030 in the maple syrup urine disease treatment due to the swift economic development. Moreover, the Change in lifestyles and the increase in obesity, diabetes, and hypercholesterolemia diseases is further anticipated to propel the growth of the maple syrup urine disease treatment in the region in the coming years.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
Maple Syrup Urine Disease Treatment market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment’s, installed base of different kind of products for Maple Syrup Urine Disease Treatment market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the Maple Syrup Urine Disease Treatment market. The data is available for historic period 2010-2020.
Competitive Landscape and Maple Syrup Urine Disease Treatment Market Share Analysis
The Maple Syrup Urine Disease Treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Maple Syrup Urine Disease Treatment market.
Some of the major players operating in the Maple Syrup Urine Disease Treatment market are:
- CENTOGENE AG - Germany
- Acer Therapeutics Inc. – U.S.
- HemoShear Therapeutics, LLC - U.S.
- Recordati SpA - Italy
- Jo Mar Laboratories - U.S.
- Siddhi Vinayaka Spechem Private Limited - India
- Baxter - U.S.
- EXOCOBIO - South Korea
- Pfizer Inc. - U.S.
- Codexis, Inc. - U.S.
- Homology Medicines, Inc. - U.S.
- Mendel Tijssen BV - Netherlands
- Biomarin Pharmaceutical Inc. - U.S.
- Vitaflo International Ltd. – U.K.
- Mead Johnson & Company, LLC - U.S.
- Nutricia Advanced Medical Nutrition - Netherlands
- Daiichi Sankyo Company, Limited - Japan
- Chiesi Farmaceutici S.p.A. - Italy
- Orphan Europe SARL - France
SKU-